Helixmith Co (084990) Fair Value & Analysis
Consumer Non-Cyclicals · KR · Market cap 158B KRW
Fair value as of: Jul 22, 2026
From 2 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 833.48 KRW to 823.10 KRW (−1.2%) since Jul 7, 2026. Share price −5.2% over the past month.
A solid business, but screening 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (899.73 KRW). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (783.11 KRW to 899.73 KRW), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 2,185 KRW – 36,273 KRW · fair‑value band 783.11 KRW – 899.73 KRW · the 3,585 KRW price screens above the 823.10 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Helixmith Co (084990) currently trades at 3,585 KRW, while our model-based Fair Value estimate is 823.10 KRW, implying the stock looks roughly 77.0% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Consumer Non-Cyclicals sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 2.9B KRW. Revenue grew 18.1% year over year. Net debt stands at 69.6B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 783.11 KRW (bear case) to 899.73 KRW (bull case); at 3,585 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 64% below its 52-week high and 29% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at 11% fair-value upside, at -77%, 084990 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: Asset-Based (2,066 KRW) versus DCF Models (1,018 KRW). Highest evidence: NCAV (Graham) (50).
Notify me when 084990 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China.
Full company description
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Helixmith Co reported revenue of 2.6B KRW in FY2025 versus 2.3B KRW in FY2021, a compound +2.9%/yr. Reported net income was −435M KRW in FY2025.
084990 screens 77% overvalued. Compare with FB →
Peer Group
Food & Tobacco · 19 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Food & Tobacco stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| FB FB | 49.00 PHP | 49.03 PHP | +0% |
| URC URC | 61.20 PHP | 47.86 PHP | -22% |
| CNPF CNPF | 32.50 PHP | 64.84 PHP | +100% |
| 540743 540743 | ₹556.65 | ₹616.73 | +11% |
| DNL DNL | 3.64 PHP | 3.43 PHP | -6% |
| RFM RFM | 5.41 PHP | 8.87 PHP | +64% |
| AXLM AXLM | 2.70 PHP | 2.89 PHP | +7% |
| EASY BIO,Inc. 353810 | 6,120 KRW | 17,633 KRW | +188% |
| LFM LFM | 26.60 PHP | 7.12 PHP | -73% |
| MSC Co 009780 | 6,020 KRW | 22,224 KRW | +269% |
Compare Helixmith Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is Helixmith Co (084990) overvalued or undervalued?
What is the fair value of 084990?
What is the quality score of 084990?
What is the revenue of Helixmith Co (084990)?
What is the net profit margin of 084990?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Helixmith Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.